This study investigates a cohort of patients treated with an anti-CTLA-4 ICI, ipilimumab, and characterizes the irAEs, evaluates irAE incidence as a predictor for improved cancer outcome, and examines whether a low NLR predicts irAE occurrence and cancer outcome. The gene discussed is CTLA4; the disease is cancer.